JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Inicio・Lista de Acciones・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Cerrado

SectorSanidad

13.31 -0.45

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

12.92

Máximo

13.68

Métricas clave
By Trading Economics
Ingresos	227M
Ventas	139M
P/B Media del Sector	5.909 60.328
Margen de beneficios	163.843
Empleados	1,796
EBITDA	1.3M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+48.7% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	2.7B
Apertura anterior	13.76
Cierre anterior	13.31

Noticias sobre sentimiento de mercado

By Acuity

50%

177 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

14.24 / 14.78 Soporte y Resistencia

Hutchison China MediTech Ltd ADR Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 abr 2026, 23:33 UTC

Acciones populares

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 abr 2026, 23:24 UTC

Ganancias

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 abr 2026, 23:15 UTC

Noticias de Eventos Importantes

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 abr 2026, 22:46 UTC

Ganancias

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 abr 2026, 22:37 UTC

Ganancias

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 abr 2026, 22:15 UTC

Ganancias

Noticias de Eventos Importantes

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 abr 2026, 23:33 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 abr 2026, 23:31 UTC

Ganancias

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 abr 2026, 23:31 UTC

Ganancias

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 abr 2026, 23:30 UTC

Ganancias

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 abr 2026, 23:30 UTC

Ganancias

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 abr 2026, 23:19 UTC

Charlas de Mercado

Ganancias

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 abr 2026, 23:09 UTC

Ganancias

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 abr 2026, 23:03 UTC

Charlas de Mercado

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 abr 2026, 23:01 UTC

Noticias de Eventos Importantes

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 abr 2026, 22:51 UTC

Ganancias

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 abr 2026, 22:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

28 abr 2026, 22:48 UTC

Charlas de Mercado

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 abr 2026, 22:40 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 abr 2026, 22:32 UTC

Ganancias

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 abr 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 abr 2026, 22:22 UTC

Ganancias

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 abr 2026, 22:17 UTC

Charlas de Mercado

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 abr 2026, 22:14 UTC

Ganancias

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 abr 2026, 22:14 UTC

Ganancias

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 abr 2026, 22:07 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparación entre iguales

Cambio de precio

Hutchison China MediTech Ltd ADR previsión

Precio Objetivo

By TipRanks

48.7% repunte

Estimación a 12 Meses

Media 20 USD 48.7%

Máximo 20 USD

Mínimo 20 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Hutchison China MediTech Ltd ADR Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

14.24 / 14.78Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bearish.

Sentimiento

By Acuity

177 / 348 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.